Oak Thistle LLC Acquires Shares of 2,023 Cencora, Inc. (NYSE:COR)

Oak Thistle LLC bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,023 shares of the company's stock, valued at approximately $455,000.

Several other hedge funds have also recently bought and sold shares of COR. Virtu Financial LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at about $1,086,000. Axxcess Wealth Management LLC raised its position in Cencora by 5.8% in the 2nd quarter. Axxcess Wealth Management LLC now owns 9,488 shares of the company's stock valued at $2,138,000 after buying an additional 517 shares during the last quarter. SYSTM Wealth Solutions LLC bought a new stake in Cencora in the 2nd quarter valued at approximately $36,000. Meiji Yasuda Asset Management Co Ltd. boosted its position in Cencora by 19.0% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,014 shares of the company's stock worth $1,130,000 after acquiring an additional 800 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Cencora by 6.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 21,366 shares of the company's stock worth $4,781,000 after acquiring an additional 1,248 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now directly owns 306,752 shares of the company's stock, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 94,696 shares of company stock valued at $22,862,734 in the last three months. 15.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on COR. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective on the stock. StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Robert W. Baird raised their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Wells Fargo & Company dropped their target price on Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a report on Friday, December 13th. Finally, UBS Group raised their price target on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $275.60.

Cencora Stock Performance

COR traded up $1.22 during trading hours on Friday, reaching $242.11. The company's stock had a trading volume of 1,492,998 shares, compared to its average volume of 1,280,327. The company's 50-day moving average is $237.65 and its 200-day moving average is $233.72. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $253.27. The firm has a market cap of $46.80 billion, a PE ratio of 32.24, a price-to-earnings-growth ratio of 1.48 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio is 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.